Avalo Therapeutics (AVTX) Stock
Avalo Therapeutics (AVTX) closed at $6.76 on Nov 20, 2026; its Tenet Score is 55 of 100 against 485 Healthcare peers.
Key stats
- Close
- $6.76
- Nov 20, 2026
- Market cap
- $390.9M
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 6.53 – 24.27
- low → high
- Tenet Score
- 55/100
- Mixed · 485 Healthcare peers
Industry: Drugs · see every company filed here →
Avalo Therapeutics Inc scores 55/100. Mixed. Strongest on financial health and value, growth is the soft spot versus 485 Healthcare peers.
Tenet Score · vs sector
n=485Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Piotroski F-Score
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
- ✓ Not-a-Value-Trap Gate
- ✕ Quality Floor
13F flows & insider trades land here.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a ful…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Wave Life Sciences Inc.WVE | 54 | $617.3M |
| Pacific Biosciences of California, IncPACB | 40 | $613.3M |
| Climb Bio Inc.CLYM | 62 | $608.5M |
| Sana Biotechnology IncSANA | 34 | $605.3M |
| Evotec SEEVO | 51 | $561.8M |
| Capricor Therapeutics IncCAPR | 51 | $554.1M |
| Phathom Pharmaceuticals, Inc.PHAT | 33 | $492.6M |
| Candel Therapeutics IncCADL | 45 | $486.4M |
| Cerus CorpCERS | 33 | $400.9M |
| Editas Medicine, Inc.EDIT | 27 | $334.9M |
Common questions
What sector and industry is Avalo Therapeutics in?
Avalo Therapeutics is in the Healthcare sector and the Drugs industry.
What is Avalo Therapeutics' Tenet Score?
Avalo Therapeutics' Tenet Score is 55 out of 100, ranked against 485 Healthcare peers as of Nov 21, 2026.




